We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+53.94%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.09B
AUM Growth
+$380M
(+22%)
Cap. Flow
-$160M
Cap. Flow
% of AUM
-7.66%
Top 10 Holdings %
Top 10 Hldgs %
62.79%
Holding
58
New
9
Increased
13
Reduced
12
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
EyePoint Inc
EYPT
|
+$31.7M |
| 2 |
ALX Oncology
ALXO
|
+$24M |
| 3 |
ABVX
Abivax
ABVX
|
+$21.7M |
| 4 |
CRGX
CARGO Therapeutics
CRGX
|
+$20.1M |
| 5 |
AUTL
Autolus Therapeutics
AUTL
|
+$19.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
APLS
Apellis Pharmaceuticals
APLS
|
+$69.8M |
| 2 |
Structure Therapeutics
GPCR
|
+$53.3M |
| 3 |
Cabaletta Bio
CABA
|
+$43.8M |
| 4 |
BridgeBio Pharma
BBIO
|
+$39.6M |
| 5 |
CBAY
Cymabay Therapeutics
CBAY
|
+$36.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Rhythm Pharmaceuticals
RYTM
$7.96B
| $25.3M | 1.21% |
550,000
-300,000
| -35% | -$9.46M |
|
|
ABVX
27
Abivax
ABVX
$11.4B
| $22.8M | 1.09% |
+2,130,000
| New | +$21.7M |
|
|
HARP
28
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $22.6M | 1.08% |
2,349,060
+2,295,000
| +4,245% | +$18M |
|
29
Spyre Therapeutics
SYRE
$9.25B
| $20.2M | 0.96% |
+937,080
| New | +$12.9M |
|
30
Insmed
INSM
$28.6B
| $17.8M | 0.85% |
575,000
| – | – |
|
31
IDEAYA Biosciences
IDYA
$3.56B
| $16M | 0.76% |
450,000
-150,000
| -25% | -$4.48M |
|
|
AXNX
32
DELISTED
Axonics, Inc. Common Stock
AXNX
| $15.6M | 0.74% |
250,000
| – | – |
|
33
Neurogene
NGNE
$712M
| $14.5M | 0.69% |
+746,180
| New | +$10.7M |
|
|
LBPH
34
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $14.2M | 0.68% |
2,353,141
| – | – |
|
35
Praxis Precision Medicines
PRAX
$10.1B
| $14.1M | 0.67% |
633,345
+12
| +0% | +$216 |
|
36
Rocket Pharmaceuticals
RCKT
$394M
| $13.5M | 0.64% |
450,000
| – | – |
|
|
RAPT
37
DELISTED
RAPT Therapeutics
RAPT
| $12.3M | 0.59% |
62,094
+21,469
| +53% | +$2.66M |
|
38
Disc Medicine
IRON
$2.97B
| $7.22M | 0.34% |
125,000
-100,000
| -44% | -$5.12M |
|
39
Stoke Therapeutics
STOK
$2.11B
| $5.72M | 0.27% |
1,087,807
| – | – |
|
40
PUT
Editas Medicine
EDIT
$442M
| $5.07M | 0.24% |
+500,000
| New | +$4.39M |
|
|
VERV
41
DELISTED
Verve Therapeutics
VERV
| $4.88M | 0.23% |
350,000
| – | – |
|
42
Lantheus
LNTH
$6.59B
| $4.65M | 0.22% |
+75,000
| New | +$5.08M |
|
|
CNTA
43
DELISTED
Centessa Pharmaceuticals
CNTA
| $4.47M | 0.21% |
561,600
| – | – |
|
44
Biohaven
BHVN
$2.21B
| $3.51M | 0.17% |
81,963
| – | – |
|
45
GH Research
GHRS
$2.08B
| $3.44M | 0.16% |
593,043
| – | – |
|
|
YARW
46
Yarrow Bioscience, Inc. Common Stock
YARW
$111M
| $3.25M | 0.16% |
+27,887
| New | +$4.35M |
|
47
BioAtla
BCAB
$5.74M
| $2.91M | 0.14% |
23,622
| – | – |
|
48
Neumora Therapeutics
NMRA
$302M
| $1.57M | 0.08% |
92,293
| – | – |
|
|
49
Cabaletta Bio
CABA
$455M
| – | – |
-2,879,424
| Closed | -$43.8M |
|
50
Cogent Biosciences
COGT
$7.24B
| – | – |
-1,000,000
| Closed | -$9.75M |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
C
TCM
BGM
Cormorant Asset Management's Q4 2023 Portfolio in Review
As of Q4 2023, Cormorant Asset Management held 58 positions worth $2.09B, up 22% from $1.71B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Cormorant Asset Management withdrew a net $160M in Q4 2023, closing 10 positions and reducing 12 holdings. Its most notable exit was Structure Therapeutics, an estimated $53.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.
Against the trend, Cormorant Asset Management opened a new position in Abivax worth $22.8M.
- Cormorant Asset Management's largest Q4 2023 buy was Abivax: 2,130,000 shares worth $22.8M.
- Cormorant Asset Management added most to EyePoint Inc in Q4 2023, an estimated $31.7M increase.
- Cormorant Asset Management's biggest Q4 2023 reduction was Apellis Pharmaceuticals, cutting an estimated $69.8M.
- Cormorant Asset Management fully exited Structure Therapeutics in Q4 2023, selling an estimated $53.3M.
- Cormorant Asset Management's ten largest holdings make up 63% of its $2.09B portfolio in Q4 2023.
- Cormorant Asset Management opened 9 new positions and closed 10 in Q4 2023.
- Cormorant Asset Management's portfolio value rose 22% quarter-over-quarter to $2.09B.
Based on Cormorant Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.